全身表现/合并症对 COPD 患者临床状态、预后、医疗资源利用的影响 (COSYCONET)
2024年4月11日 更新者：Claus Vogelmeier、Philipps University Marburg Medical Center
全身表现/合并症对 COPD 患者临床状态、预后和医疗资源利用的影响
本研究的目的是确定肺外疾病的患病率和严重程度，并量化肺外器官表现对 COPD 患者发病率和死亡率的影响。
此外，研究人员还评估了全身炎症与器官受累之间的关系。
研究概览
地位
完全的
详细说明
慢性疾病和合并症对个人生活和医疗保健使用的影响越来越大，例如慢性阻塞性肺病 (COPD)。
目前，缺乏允许集成视图的独立、全面的数据库。
该研究将首次建立一个大型、综合的纵向数据库，涵盖广泛的合并症和系统改变的标志。
这些数据在通过合并症的模式和风险概况揭示 COPD 的特定表型、实现更精确的诊断和治疗目标以及有效的资源分配方面具有独特的价值。
研究类型
观察性的
注册 (实际的)
2741
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
-
Berlin、德国、13125
- Ev. Lungenklinik (ELK), Krankenhausbetriebs gGmbH, Pneumologische Klinik
-
Borstel、德国、23845
- Forschungszentrum Borstel, Medizinische Klinik
-
Donaustauf、德国、93093
- Klinik Donaustauf, Zentrum für Pneumologie
-
Essen、德国、45239
- Ruhrlandklinik Essen, Westdeutsches Lungenzentrum
-
Gauting、德国、82131
- EvA-Study Center, Helholtz Zentrum München
-
Gießen、德国
- Justus-Liebig-Universität, Medizinische Klinik II
-
Greifswald、德国、17475
- Universitätsklinikum Greifswald der Ernst-Moritz-Arndt Universität, Zentrum für Innere Medizin
-
Großhansdorf、德国、22927
- Krankenhaus Großhansdorf, Pneumologisches Forschungsinstitut
-
Hamburg、德国、20354
- HIT-Hamburger Institut für Therapieforschung GmbH
-
Hannover、德国、30625
- Medical School Hannover, Dep. of Pneumology
-
Heidelberg、德国、69126
- Thoraxklinik Heidelberg
-
Homburg、德国、66421
- University of Saarland
-
Immenhausen、德国、34376
- Fachklinik für Lungenerkrankungen Philippsstiftung ev.
-
Kiel、德国、24105
- Universitiy of Kiel
-
Leipzig、德国、04103
- Universitätsklinikum Leipzig, Department Innere Medizin
-
Marburg、德国、35042
- Philipps-University Marburg, Medical Center, Dep. of Pneumology
-
Munic、德国、80336
- Ludwig-Maximilians-University, Medizinische Klinik Innenstadt
-
Nürnberg、德国、90419
- Klinikum Nürnberg, Medizinische Klinik 3, Schwerpunkt Pneumologie, Allergologie und Schlafmedizin
-
Rostock、德国、18057
- Universitätsklinikum Rostock, Zentrum für Innere Medizin, Abt. f. Pneumologie
-
Schönau am Königssee、德国、83471
- Klinikum Berchtesgardener Land, Schön Kliniken, Fachzentrum für Pneumologie, Allergologie und Schlafmedizin
-
Solingen、德国、42699
- Krankenhaus Bethanien gGmbH
-
Würzburg、德国、97067
- Missionsärztliche Klinik GmbH, Innere Medizin
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
40年 及以上 (成人、年长者)
接受健康志愿者
不
取样方法
非概率样本
研究人群
由于最初的招募策略并没有像预期的那样成功，因此将招募模式扩展到其他医生、患者团体和组织，并向当地媒体投放广告。
招聘得到马尔堡协调中心组织的专业交流措施的支持。
描述
纳入标准：
- 40岁以上
- COPD（GOLD 标准）或慢性支气管炎的诊断
- 知情同意
- 可用于 18 个月以上的重复研究访问
排除标准：
- 接受过大肺部手术（例如 肺缩小术、肺移植）
- 最近 4 周内中度或重度恶化
- 患有肺部肿瘤
- 无法行走或无法理解项目的意图
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
18 个月时 BODE 评分相对于基线的变化
大体时间：初次访问时、18、36、54、72、90 和 108 个月后
|
BODE 评分包括 BMI、气道阻塞、呼吸困难和运动能力，是 COPD 患者死亡的良好预测指标。
进展定义为在观察期间 BODE 分数的变化 >=1 点。
|
初次访问时、18、36、54、72、90 和 108 个月后
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
慢性阻塞性肺病相关死亡率
大体时间：18个月后
|
6、18、36、54、72、90 和 108 个月后死亡率升高
|
18个月后
|
|
慢性阻塞性肺病相关住院
大体时间：18、36、54、72、90 和 108 个月后
|
每次就诊的住院率都有所提高。
|
18、36、54、72、90 和 108 个月后
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 学习椅：Claus Vogelmeier, Prof.、Philipps University Marburg Medical Center
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Jorres RA, Welte T, Bals R, Koch A, Schnoor M, Vogelmeier C. [Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease--an overview of the cohort study COSYCONET]. Dtsch Med Wochenschr. 2010 Mar;135(10):446-9. doi: 10.1055/s-0030-1249185. Epub 2010 Mar 2. German.
- Wacker ME, Jorres RA, Schulz H, Heinrich J, Karrasch S, Karch A, Koch A, Peters A, Leidl R, Vogelmeier C, Holle R; COSYCONET-Consortium. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respir Med. 2016 Feb;111:39-46. doi: 10.1016/j.rmed.2015.12.001. Epub 2015 Dec 10.
- Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, Biederer J, Heinrich J, Schulz H, Glaser S, Holle R, Watz H, Korn S, Adaskina N, Biertz F, Vogel C, Vestbo J, Wouters EF, Rabe KF, Sohler S, Koch A, Jorres RA; COSYCONET Study Group. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016 May;114:27-37. doi: 10.1016/j.rmed.2016.03.008. Epub 2016 Mar 11.
- Wacker ME, Jorres RA, Karch A, Wilke S, Heinrich J, Karrasch S, Koch A, Schulz H, Watz H, Leidl R, Vogelmeier C, Holle R; COSYCONET-Consortium. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016 May 10;16(1):70. doi: 10.1186/s12890-016-0238-9.
- Wacker ME, Jorres RA, Karch A, Koch A, Heinrich J, Karrasch S, Schulz H, Peters A, Glaser S, Ewert R, Baumeister SE, Vogelmeier C, Leidl R, Holle R; COSYCONET study group. Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies. Respir Res. 2016 Jul 12;17(1):81. doi: 10.1186/s12931-016-0401-0.
- Lucke T, Herrera R, Wacker M, Holle R, Biertz F, Nowak D, Huber RM, Sohler S, Vogelmeier C, Ficker JH, Muckter H, Jorres RA; COSYCONET-Consortium. Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies - A Novel Stepwise Approach by Evaluation of Medication. PLoS One. 2016 Oct 28;11(10):e0163408. doi: 10.1371/journal.pone.0163408. eCollection 2016.
- Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, Waschki B, Kleibrink BE, Welte T, Bals R, Schulz H, Biertz F, Young D, Vogelmeier CF, Jorres RA. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir Med. 2018 Apr;137:14-22. doi: 10.1016/j.rmed.2018.02.011. Epub 2018 Feb 19.
- Kahnert K, Lucke T, Huber RM, Behr J, Biertz F, Vogt A, Watz H, Alter P, Fahndrich S, Bals R, Holle R, Karrasch S, Sohler S, Wacker M, Ficker JH, Parhofer KG, Vogelmeier C, Jorres RA; COSYCONET consortium. Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS One. 2017 May 15;12(5):e0177501. doi: 10.1371/journal.pone.0177501. eCollection 2017.
- Fahndrich S, Biertz F, Karch A, Kleibrink B, Koch A, Teschler H, Welte T, Kauczor HU, Janciauskiene S, Jorres RA, Greulich T, Vogelmeier CF, Bals R; COSYCONET investigators. Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. Respir Res. 2017 Sep 15;18(1):171. doi: 10.1186/s12931-017-0655-1.
- Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jorres RA. The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.
- Kahnert K, Lucke T, Biertz F, Lechner A, Watz H, Alter P, Bals R, Behr J, Holle R, Huber RM, Karrasch S, Stubbe B, Wacker M, Sohler S, Wouters EF, Vogelmeier C, Jorres RA; COSYCONET study group. Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Respir Res. 2017 Jan 13;18(1):14. doi: 10.1186/s12931-016-0499-0.
- Houben-Wilke S, Jorres RA, Bals R, Franssen FM, Glaser S, Holle R, Karch A, Koch A, Magnussen H, Obst A, Schulz H, Spruit MA, Wacker ME, Welte T, Wouters EF, Vogelmeier C, Watz H. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am J Respir Crit Care Med. 2017 Jan 15;195(2):189-197. doi: 10.1164/rccm.201602-0354OC.
- Karl FM, Holle R, Bals R, Greulich T, Jorres RA, Karch A, Koch A, Karrasch S, Leidl R, Schulz H, Vogelmeier C, Wacker ME; COSYCONET Study Group. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respir Res. 2017 Apr 17;18(1):60. doi: 10.1186/s12931-017-0543-8.
- Smid DE, Franssen FME, Gonik M, Miravitlles M, Casanova C, Cosio BG, de Lucas-Ramos P, Marin JM, Martinez C, Mir I, Soriano JB, de Torres JP, Agusti A, Atalay NB, Billington J, Boutou AK, Brighenti-Zogg S, Chaplin E, Coster S, Dodd JW, Durr S, Fernandez-Villar A, Groenen MTJ, Guimaraes M, Hejduk K, Higgins V, Hopkinson NS, Horita N, Houben-Wilke S, Janssen DJA, Jehn M, Joerres R, Karch A, Kelly JL, Kim YI, Kimura H, Koblizek V, Kocks JH, Kon SSC, Kwon N, Ladeira I, Lee SD, Leuppi JD, Locantore N, Lopez-Campos JL, D-C Man W, Maricic L, Mendoza L, Miedinger D, Mihaltan F, Minami S, van der Molen T, Murrells TJ, Nakken N, Nishijima Y, Norman IJ, Novotna B, O'Donnell DE, Ogata Y, Pereira ED, Piercy J, Price D, Pothirat C, Raghavan N, Ringbaek T, Sajkov D, Sigari N, Singh S, Small M, da Silva GF, Tanner RJ, Tsiligianni IG, Tulek B, Tzanakis N, Vanfleteren LEGW, Watz H, Webb KA, Wouters EFM, Xie GG, Yoshikawa M, Spruit MA. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. J Am Med Dir Assoc. 2017 Dec 1;18(12):1097.e11-1097.e24. doi: 10.1016/j.jamda.2017.09.003.
- Wacker ME, Kitzing K, Jorres RA, Leidl R, Schulz H, Karrasch S, Karch A, Koch A, Vogelmeier CF, Holle R. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2017 Dec 4;12:3437-3448. doi: 10.2147/COPD.S141852. eCollection 2017.
- Alter P, Jorres RA, Watz H, Welte T, Glaser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF. Left ventricular volume and wall stress are linked to lung function impairment in COPD. Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.
- Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jorres RA. Influence of body mass on predicted values of static hyperinflation in COPD. Int J Chron Obstruct Pulmon Dis. 2018 Aug 23;13:2551-2555. doi: 10.2147/COPD.S164096. eCollection 2018.
- Alter P, Jorres RA. Concomitance of cardiovascular and pulmonary disorders: mutual bystanders or causal interactions? Kardiol Pol. 2018;76(7):1027-1028. doi: 10.5603/KP.2018.0132. No abstract available.
- Graf J, Lucke T, Herrera R, Watz H, Holle R, Vogelmeier C, Ficker JH, Jorres RA. Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD. Pulm Pharmacol Ther. 2018 Apr;49:123-129. doi: 10.1016/j.pupt.2018.01.011. Epub 2018 Feb 5.
- Graf J, Jorres RA, Lucke T, Nowak D, Vogelmeier CF, Ficker JH. Medical Treatment of COPD. Dtsch Arztebl Int. 2018 Sep 14;155(37):599-605. doi: 10.3238/arztebl.2018.0599.
- Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fahndrich S, Jorres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H. Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:2999-3002. doi: 10.2147/COPD.S165909. eCollection 2018. No abstract available.
- Kahnert K, Alter P, Welte T, Huber RM, Behr J, Biertz F, Watz H, Bals R, Vogelmeier CF, Jorres RA. Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. Respir Res. 2018 Jun 4;19(1):110. doi: 10.1186/s12931-018-0815-y.
- Kahnert K, Jobst B, Biertz F, Biederer J, Watz H, Huber RM, Behr J, Grenier PA, Alter P, Vogelmeier CF, Kauczor HU, Jorres RA. Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans. Chron Respir Dis. 2019 Jan-Dec;16:1479972318775423. doi: 10.1177/1479972318775423. Epub 2018 May 9.
- Kaireit TF, Voskrebenzev A, Gutberlet M, Freise J, Jobst B, Kauczor HU, Welte T, Wacker F, Vogel-Claussen J. Comparison of quantitative regional perfusion-weighted phase resolved functional lung (PREFUL) MRI with dynamic gadolinium-enhanced regional pulmonary perfusion MRI in COPD patients. J Magn Reson Imaging. 2019 Apr;49(4):1122-1132. doi: 10.1002/jmri.26342. Epub 2018 Oct 22.
- Keller A, Fehlmann T, Ludwig N, Kahraman M, Laufer T, Backes C, Vogelmeier C, Diener C, Biertz F, Herr C, Jorres RA, Lenhof HP, Meese E, Bals R; COSYCONET Study Group. Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development. Genomics Proteomics Bioinformatics. 2018 Jun;16(3):162-171. doi: 10.1016/j.gpb.2018.06.001. Epub 2018 Jul 5.
- Triphan SMF, Biederer J, Burmester K, Fellhauer I, Vogelmeier CF, Jorres RA, Kauczor HU, Heussel CP, Wielputz MO, Jobst BJ. Design and application of an MR reference phantom for multicentre lung imaging trials. PLoS One. 2018 Jul 5;13(7):e0199148. doi: 10.1371/journal.pone.0199148. eCollection 2018.
- Alter P, Watz H, Kahnert K, Rabe KF, Biertz F, Fischer R, Jung P, Graf J, Bals R, Vogelmeier CF, Jorres RA. Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD. Respir Res. 2019 Mar 27;20(1):61. doi: 10.1186/s12931-019-1025-y.
- Byng D, Lutter JI, Wacker ME, Jorres RA, Liu X, Karrasch S, Schulz H, Vogelmeier C, Holle R. Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET. Int J Chron Obstruct Pulmon Dis. 2019 Jul 5;14:1423-1439. doi: 10.2147/COPD.S201899. eCollection 2019.
- Trudzinski FC, Kahnert K, Vogelmeier CF, Alter P, Seiler F, Fahndrich S, Watz H, Welte T, Speer T, Zewinger S, Biertz F, Kauczor HU, Jorres RA, Bals R; COSYCONET consortium. Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort. Respir Med. 2019 Jul-Aug;154:18-26. doi: 10.1016/j.rmed.2019.06.007. Epub 2019 Jun 11.
- Trudzinski FC, Alqudrah M, Omlor A, Zewinger S, Fliser D, Speer T, Seiler F, Biertz F, Koch A, Vogelmeier C, Welte T, Watz H, Waschki B, Fahndrich S, Jorres R, Bals R; German COSYCONET consortium. Consequences of chronic kidney disease in chronic obstructive pulmonary disease. Respir Res. 2019 Jul 12;20(1):151. doi: 10.1186/s12931-019-1107-x.
- von Siemens SM, Jorres RA, Behr J, Alter P, Lutter J, Lucke T, Sohler S, Welte T, Watz H, Vogelmeier CF, Trudzinski F, Rief W, Herbig B, Kahnert K; COSYCONET study group. Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study. Respir Res. 2019 Feb 11;20(1):30. doi: 10.1186/s12931-019-0997-y.
- Alter P, Mayerhofer BA, Kahnert K, Watz H, Waschki B, Andreas S, Biertz F, Bals R, Vogelmeier CF, Jorres RA. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2019 Sep 20;14:2163-2172. doi: 10.2147/COPD.S209343. eCollection 2019.
- Keller A, Ludwig N, Fehlmann T, Kahraman M, Backes C, Kern F, Vogelmeier CF, Diener C, Fischer U, Biertz F, Herr C, Jorres RA, Lenhof HP, Bals R, Meese E. Low miR-150-5p and miR-320b Expression Predicts Reduced Survival of COPD Patients. Cells. 2019 Sep 27;8(10):1162. doi: 10.3390/cells8101162.
- Konigsdorfer N, Jorres RA, Sohler S, Welte T, Behr J, Ficker JH, Bals R, Watz H, Lutter JI, Lucke T, Biertz F, Alter P, Vogelmeier CF, Kahnert K. Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort. Patient Prefer Adherence. 2019 Oct 10;13:1711-1721. doi: 10.2147/PPA.S223438. eCollection 2019.
- von Siemens SM, Perneczky R, Vogelmeier CF, Behr J, Kauffmann-Guerrero D, Alter P, Trudzinski FC, Bals R, Grohe C, Sohler S, Waschki B, Lutter JI, Welte T, Jorres RA, Kahnert K; COSYCONET study group. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort. Respir Res. 2019 Nov 14;20(1):257. doi: 10.1186/s12931-019-1217-5.
- Kahnert K, Fohrenbach M, Lucke T, Alter P, Trudzinski FT, Bals R, Lutter JI, Timmermann H, Sohler S, Forderreuther S, Nowak D, Watz H, Waschki B, Behr J, Welte T, Vogelmeier CF, Jorres RA. The impact of COPD on polyneuropathy: results from the German COPD cohort COSYCONET. Respir Res. 2020 Jan 20;21(1):28. doi: 10.1186/s12931-020-1293-6.
- Lutter JI, Jorres RA, Kahnert K, Schwarzkopf L, Studnicka M, Karrasch S, Schulz H, Vogelmeier CF, Holle R; COSYCONET Study Group. Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort. BMC Pulm Med. 2020 May 29;20(1):148. doi: 10.1186/s12890-020-1147-5.
- Trudzinski FC, Jorres RA, Alter P, Kahnert K, Waschki B, Herr C, Kellerer C, Omlor A, Vogelmeier CF, Fahndrich S, Watz H, Welte T, Jany B, Sohler S, Biertz F, Herth F, Kauczor HU, Bals R; COSYCONET consortium. Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET. Sci Rep. 2020 Jun 29;10(1):10544. doi: 10.1038/s41598-020-67197-x.
- Marietta von Siemens S, Alter P, Lutter JI, Kauczor HU, Jobst B, Bals R, Trudzinski FC, Sohler S, Behr J, Watz H, Waschki B, Bewig B, Jones PW, Welte T, Vogelmeier CF, Jorres RA, Kahnert K; COSYCONET study group; Names of participating study nurses. CAT score single item analysis in patients with COPD: Results from COSYCONET. Respir Med. 2019 Nov;159:105810. doi: 10.1016/j.rmed.2019.105810. Epub 2019 Nov 7.
- Lutter JI, Lukas M, Schwarzkopf L, Jorres RA, Studnicka M, Kahnert K, Karrasch S, Bewig B, Vogelmeier CF, Holle R; COSYCONET Study Group. Utilization and determinants of use of non-pharmacological interventions in COPD: Results of the COSYCONET cohort. Respir Med. 2020 Sep;171:106087. doi: 10.1016/j.rmed.2020.106087. Epub 2020 Jul 12.
- Waschki B, Alter P, Zeller T, Magnussen C, Neumann JT, Twerenbold R, Sinning C, Herr C, Kahnert K, Fahndrich S, Blankenberg S, Rabe KF, Welte T, Jorres RA, Vogelmeier CF, Bals R, Watz H; German COSYCONET Cohort. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. Eur Respir J. 2020 Feb 27;55(2):1901314. doi: 10.1183/13993003.01314-2019. Print 2020 Feb.
- Omlor AJ, Trudzinski FC, Alqudrah M, Seiler F, Biertz F, Vogelmeier CF, Welte T, Watz H, Waschki B, Brinker TJ, Andreas S, Fahndrich S, Alter P, Jorres RA, Bohm M, Bals R; German COSYCONET Cohort. Time-updated resting heart rate predicts mortality in patients with COPD. Clin Res Cardiol. 2020 Jun;109(6):776-786. doi: 10.1007/s00392-019-01572-1. Epub 2019 Nov 16.
- Lommatzsch M, Speer T, Herr C, Jorres RA, Watz H, Muller A, Welte T, Vogelmeier CF, Bals R; COSYCONET study group. IgE is associated with exacerbations and lung function decline in COPD. Respir Res. 2022 Jan 4;23(1):1. doi: 10.1186/s12931-021-01847-0.
- Kellerer C, Jorres RA, Schneider A, Alter P, Kauczor HU, Jobst B, Biederer J, Bals R, Watz H, Behr J, Kauffmann-Guerrero D, Lutter J, Hapfelmeier A, Magnussen H, Trudzinski FC, Welte T, Vogelmeier CF, Kahnert K. Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET. Respir Res. 2021 Sep 9;22(1):242. doi: 10.1186/s12931-021-01837-2.
- Trudzinski FC, Jorres RA, Alter P, Walter J, Watz H, Koch A, John M, Lommatzsch M, Vogelmeier CF, Kauczor HU, Welte T, Behr J, Tufman A, Bals R, Herth FJF, Kahnert K; COSYCONET Study Group. Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET. Sci Rep. 2022 May 24;12(1):8790. doi: 10.1038/s41598-022-12828-8.
- Kahnert K, Jorres RA, Lucke T, Trudzinski FC, Mertsch P, Bickert C, Ficker JH, Behr J, Bals R, Watz H, Welte T, Vogelmeier CF, Alter P; COSYCONET Study Group. Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET. Int J Chron Obstruct Pulmon Dis. 2021 Nov 24;16:3189-3199. doi: 10.2147/COPD.S335029. eCollection 2021.
- Trudzinski FC, Kellerer C, Jorres RA, Alter P, Lutter JI, Trinkmann F, Herth FJF, Frankenberger M, Watz H, Vogelmeier CF, Kauczor HU, Welte T, Behr J, Bals R, Kahnert K. Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities. Clin Res Cardiol. 2023 Feb;112(2):177-186. doi: 10.1007/s00392-021-01915-x. Epub 2021 Jul 31.
- Kellerer C, Kahnert K, Trudzinski FC, Lutter J, Berschneider K, Speicher T, Watz H, Bals R, Welte T, Vogelmeier CF, Jorres RA, Alter P. COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort. Respir Med. 2021 Aug-Sep;185:106461. doi: 10.1016/j.rmed.2021.106461. Epub 2021 May 29.
- Alter P, Orszag J, Kellerer C, Kahnert K, Speicher T, Watz H, Bals R, Welte T, Vogelmeier CF, Jorres RA. Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET. ERJ Open Res. 2020 Jul 27;6(3):00092-2020. doi: 10.1183/23120541.00092-2020. eCollection 2020 Jul.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2010年11月1日
初级完成 (实际的)
2013年12月1日
研究完成 (实际的)
2023年12月1日
研究注册日期
首次提交
2010年11月18日
首先提交符合 QC 标准的
2010年11月22日
首次发布 (估计的)
2010年11月23日
研究记录更新
最后更新发布 (实际的)
2024年4月12日
上次提交的符合 QC 标准的更新
2024年4月11日
最后验证
2024年4月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.